Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD

Abstract Background To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. Methods Observational clinical study wa...

Full description

Bibliographic Details
Main Authors: Maria Waizel, Margarita G. Todorova, Michael Masyk, Katharina Wolf, Annekatrin Rickmann, Khaled Helaiwa, Björn R. Blanke, Peter Szurman
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Ophthalmology
Subjects:
Vascular endothelial growth factor a
Ranibizumab
Aflibercept
Bevacizumab
VEGF switch
Vascular endothelial growth factor
Online Access:http://link.springer.com/article/10.1186/s12886-017-0471-x

Internet

http://link.springer.com/article/10.1186/s12886-017-0471-x

Similar Items